Retatrutide (LY3437943) is a synthetic tri-agonist research peptide with binding activity to the GLP-1, GIP, and glucagon receptor — available in 10 mg, 20 mg, and 30 mg per vial.
Externally tested by an independent EU laboratory. Purity ≥ 99% confirmed via HPLC analysis and mass spectrometry. Certificate of Analysis (COA) per lot number available.
Lyophilized powder. Shipped from Dutch stock, sent with cool pack. Ordered before 2 PM — shipped the same day.
⚠ Intended for scientific and laboratory research only. Not for human consumption. By ordering, you confirm to be 18+ and agree to our terms of use.
✓ Per batch afzonderlijk getest
✓ Inclusief Certificate of Analysis (COA)
✓ Verzending binnen de EU met traceerbaar batchnummer
Retatrutide (also known by the research code LY3437943) is a synthetic peptide being studied in scientific research as a triple receptor agonist. The compound has affinity for three receptor types simultaneously: the GLP-1 receptor (Glucagon-like Peptide-1), the GIP receptor (Glucose-dependent Insulinotropic Polypeptide), and the glucagon receptor.
Retatrutide is an analog that originated from Eli Lilly's research program. It is also known as a "triple agonist" due to its simultaneous binding activity to multiple metabolic receptor systems. The compound is the subject of ongoing scientific research and has not been approved as a drug by the EMA, FDA, or any other regulatory authority.
At Peptidera, we supply Retatrutide exclusively as a research peptide, intended for use in controlled laboratory environments by qualified researchers.
Scientific context: Retatrutide is being investigated in scientific literature as a model compound for studying energy homeostasis, metabolic regulation, and insulin secretion at the cellular level. All available data come from preclinical and early clinical research.
Retatrutide (also known by the research code LY3437943) is a synthetic peptide being studied in scientific research as a triple receptor agonist. The compound has affinity for three receptor types simultaneously: the GLP-1 receptor (Glucagon-like Peptide-1), the GIP receptor (Glucose-dependent Insulinotropic Polypeptide), and the glucagon receptor.
Retatrutide is an analog that originated from Eli Lilly's research program. It is also known as a "triple agonist" due to its simultaneous binding activity to multiple metabolic receptor systems. The compound is the subject of ongoing scientific research and has not been approved as a drug by the EMA, FDA, or any other regulatory authority.
At Peptidera, we supply Retatrutide exclusively as a research peptide, intended for use in controlled laboratory environments by qualified researchers.
Scientific context: Retatrutide is being investigated in scientific literature as a model compound for studying energy homeostasis, metabolic regulation, and insulin secretion at the cellular level. All available data come from preclinical and early clinical research.
